Positive Five-Year Results From The Global Ovation® Pivotal Trial Presented At 2016 VEITH Symposium

IRVINE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive 5-year safety and effectiveness clinical data from the global Ovation Pivotal Trial at the 2016 VEITH symposium. The results were presented by Manish Mehta, MD, MPH, Director, Vascular Health Partners of Community Care Physicians, PC and the U.S. principal investigator for the global Ovation Pivotal Trial.

The Ovation Pivotal Trial included a total of 161 patients, enrolled in Chile, Germany and USA from November 2009 to December 2011. Through five years, the key highlights from the data included:
  • Broad patient applicability, with 40% of the patients treated outside the labeled indications of other endovascular aortic repair (EVAR) devices
  • Stable aortic neck diameters with an average expansion of 0.1%, compared to 25% as reported with other EVAR devices 
  • 97.5% Freedom from secondary interventions related to type 1 endoleak
  • No migration or conversions

Dr. Mehta commented, "The five-year data from the Ovation Pivotal Trial confirms the long-term safety and durability of the Ovation system.  The study included the broadest range of AAA patients ever treated in an endovascular AAA IDE trial, and demonstrates the effectiveness of Ovation system's ultra-low profile delivery system and polymer sealing technology."

John McDermott, Chief Executive Officer of Endologix, said, "Completion of the five-year follow-up is an important milestone that validates the long-term durability of EVAR with the Ovation system. It also demonstrates the capability that the Ovation system enables physicians to treat more AAA patients than other devices.  We would like to thank Dr. Mehta and all of the investigators for their participation in the clinical trial and congratulate them for their outstanding results."

If you liked this article you might like

Endologix Poised for a Potentially Volatile Breakout

5 Stocks Trending Close to Major Breakouts

5 Stocks Set for Explosive Breakouts

These 5 Stocks Under $10 Could Make You a Lot of Money

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains